| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.00B | 9.45B | 9.49B | 10.11B | 9.39B | 7.84B |
| Gross Profit | 1.78B | 1.73B | 1.65B | 1.95B | 1.94B | 1.39B |
| EBITDA | 569.20M | 510.70M | 494.50M | 780.20M | 795.70M | 385.80M |
| Net Income | 223.50M | 131.30M | -35.40M | 196.40M | 250.00M | -220.50M |
Balance Sheet | ||||||
| Total Assets | 7.69B | 7.55B | 7.77B | 7.95B | 7.89B | 7.34B |
| Cash, Cash Equivalents and Short-Term Investments | 634.40M | 793.30M | 767.70M | 644.50M | 770.70M | 1.07B |
| Total Debt | 3.11B | 3.31B | 3.57B | 3.60B | 3.66B | 3.96B |
| Total Liabilities | 5.73B | 5.79B | 6.10B | 6.29B | 6.44B | 6.24B |
| Stockholders Equity | 1.96B | 1.75B | 1.68B | 1.66B | 1.45B | 1.09B |
Cash Flow | ||||||
| Free Cash Flow | 178.50M | 167.00M | 101.20M | -1.60M | 495.70M | -79.20M |
| Operating Cash Flow | 198.30M | 208.00M | 152.20M | 49.10M | 549.50M | -38.20M |
| Investing Cash Flow | -62.10M | 81.20M | 48.90M | -120.70M | -749.50M | -257.80M |
| Financing Cash Flow | -289.00M | -253.40M | -120.80M | -79.30M | -65.80M | 571.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $16.37B | 26.59 | 9.14% | ― | 12.51% | 32.34% | |
70 Outperform | $49.08B | 40.74 | 14.26% | ― | 14.61% | 30.19% | |
69 Neutral | $3.83B | 17.33 | 12.21% | ― | 6.77% | 150.72% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
61 Neutral | $28.35B | 1,301.36 | 0.25% | ― | 14.61% | -87.93% | |
59 Neutral | $3.20B | 30.59 | 8.08% | 0.68% | 22.22% | 94.52% | |
56 Neutral | $1.08B | -161.02 | -1.09% | 1.80% | 20.74% | 78.92% |
Cushman & Wakefield announced its financial targets for 2026-2028 during an investor day scheduled for December 4, 2025. The company aims for significant growth, including a 15-20% annual increase in adjusted earnings per share and a 6-8% rise in organic fee revenue. By 2028, it targets a 200% increase in cross-sell fee revenue and a 96% client retention rate. The company also plans to improve its net debt leverage to 2x by the end of 2028, with a strong free cash flow conversion expected to result in approximately $800 million in cumulative free cash flow starting in 2026. These strategic goals are part of Cushman & Wakefield’s broader effort to enhance client relationships and transform its platform for better productivity and revenue generation.
On October 21, 2025, Cushman & Wakefield announced an amendment to its Credit Agreement, reducing revolving commitments from $1.1 billion to $1 billion and extending the maturity date to October 21, 2030. This move, which was oversubscribed, reflects lender confidence in the company’s financial strategy and aims to enhance capital efficiency and liquidity.
On October 16, 2025, Cushman & Wakefield shareholders approved the company’s plan to change its jurisdiction of incorporation from England and Wales to Bermuda. This decision was made during a series of shareholder meetings where various proposals, including the issuance of new shares and governance changes, were overwhelmingly supported. The redomiciliation is expected to reduce administrative burdens and costs while maintaining strong corporate governance and capital flexibility. The company plans to finalize the redomiciliation by November 27, 2025, subject to legal and regulatory procedures.
On October 2, 2025, Cushman & Wakefield announced the successful repricing of its $840 million Term Loan, reducing the interest rate by 25 basis points. This move, part of the company’s strategy for debt reduction and disciplined growth, reflects strong momentum and lender support, having already prepaid $200 million of its Term Loan in 2025.